Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease

Neuroscience

Volumn 268, Issue , 2014, Pages 265-275

  Hui, Y P ^a   Zhang, Q J ^a   Zhang, L ^a   Chen, L ^a   Guo, Y ^a   Qiao, H F ^a   Wang, Y ^a   Liu, J ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Depression; Parkinson's disease; Prelimbic medial prefrontal cortex; Rat

Indexed keywords

OXIDOPAMINE; SEROTONIN 1A RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; EXCITATORY AMINO ACID TRANSPORTER 3; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 ANTAGONIST; SEROTONIN AGONIST; SLC1A1 PROTEIN, RAT; SUGAR INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; BRAIN DAMAGE; BRAIN REGION; CONTROLLED STUDY; DISEASE ACTIVITY; FORCED SWIM TEST; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; DEPRESSION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; FOOD PREFERENCE; METABOLISM; NERVE CELL; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SUGAR INTAKE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIETARY SUCROSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXCITATORY AMINO ACID TRANSPORTER 3; FOOD PREFERENCES; MALE; MEDIAL FOREBRAIN BUNDLE; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIPERAZINES; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 84898467233     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.03.033     Document Type: Article

References (67)

1. Arakawa S., Shirayama Y., Fujita Y., Ishima T., Horio M., Muneoka K., Iyo M., Hashimoto K. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 2012, 100:601-606.
2. Araneda R., Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991, 40:399-412.
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
5. 1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
6. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., Morgese M.G., Popoli P., Alleva E. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008, 86:2050-2061.
7. Carvalho M.M., Campos F.L., Coimbra B., Pego J.M., Rodrigues C., Lima R., Rodrigues A.J., Sousa N., Salgado A.J. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013, 8:14.
8. 1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999, 10:1441-1445.
9. 2A receptors in depression. J Psychiatry Neurosci 2004, 29:252-265.
10. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2001, 21:9917-9929.
11. Delaville C., Chetrit J., Abdallah K., Morin S., Cardoit L., De Deurwaerdere P., Benazzouz A. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis 2012, 45:763-773.
12. Doris A., Ebmeier K., Shajahan P. Depressive illness. Lancet 1999, 354:1369-1375.
13. 3H] paroxetine binding to the 5-hydroxytryptamine uptake site in an animal model of depression. J Neurochem 1991, 56:1581-1586.
14. Eskow Jaunarajs K.L., Dupre K.B., Ostock C.Y., Button T., Deak T., Bishop C. Behavioral and neurochemical effects of chronic l-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol 2010, 21:627-637.
15. Eskow Jaunarajs K.L., George J.A., Bishop C. l-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience 2012, 218:243-256.
16. 7 receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopamine-lesioned rats: an electrophysiological study. Neuroscience 2011, 190:328-338.
17. Fuller R.W. Role of serotonin in therapy of depression and related disorders. J Clin Psychiatry 1991, 52:S52-S57.
18. 3 receptors in 6-hydroxydopamine-induced parkinsonian rats. Neuroscience 2010, 169:1315-1325.
19. 1A receptor agonist and expression of the receptor in parvalbumin-positive neurons in the rat. Neurochem Int 2011, 59:618-627.
20. Hajos M., Richards C.D., Szekely A.D., Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998, 87:95-108.
21. Hamani C., Diwan M., Isabella S., Lozano A.M., Nobrega J.N. Effects of different stimulation parameters on the antidepressant-like response of medial prefrontal cortex deep brain stimulation in rats. J Psychiatr Res 2010, 44:683-687.
22. Hamani C., Diwan M., Macedo C.E., Brandão M.L., Shumake J., Gonzalez-Lima F., Raymond R., Lozano A.M., Fletcher P.J., Nobrega J.N. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry 2010, 67:117-124.
23. Hamani C., Nobrega J.N. Deep brain stimulation in clinical trials and animal models of depression. Eur J Neurosci 2010, 32:1109-1117.
24. Heidbreder C.A., Groenewegen H.J. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev 2003, 27:555-579.
25. 1A receptor stimulation in the rat. Neurochem Int 2012, 61:1344-1356.
26. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95:163-212.
27. Iyo A.H., Kieran N., Chandran A., Albert P.R., Wicks I., Bissette G., Austin M.C. Differential regulation of the serotonin1A transcriptional modulators five prime repressor element under dual repression-1 and nuclear-deformed epidermal autoregulatory factor by chronic stress. Neuroscience 2009, 163:1119-1127.
28. 1A receptor binding induced by chronic mild stress, a depression-like symptom. Arch Pharm Res 2004, 27:1065-1072.
29. Jungnickel J., Kalve I., Reimers L., Nobre A., Wesemann M., Ratzka A., Halfer N., Lindemann C., Schwabe K., Töllner K., Gernert M., Grothe C. Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Behav Brain Res 2011, 216:129-135.
30. 1A receptor but not Freud-1 or NUDR in the rat prefrontal cortex. Neurosci Lett 2010, 469:380-384.
31. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
32. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology 2008, 197:279-293.
33. Likhtik E., Pelletier J.G., Paz R., Pare D. Prefrontal control of the amygdala. J Neurosci 2005, 25:7429-7437.
34. Lozano A.M., Dostrovsky J., Chen R., Ashby P. Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol 2002, 1:225-231.
35. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999, 21:99S-105S.
36. 1A agonist, in the learned helplessness paradigm: evidence for a postsynaptic mechanism. Behav Brain Res 1990, 38:135-144.
37. 1A receptor activation in mice. Eur J Pharmacol 1995, 280:235-238.
38. 1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem 2007, 50:5024-5033.
39. McDonald A.J., Mascagni F., Guo L. Projections of the medial and lateral prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in the rat. Neuroscience 1996, 71:55-75.
40. McLaughlin R.J., Hill M.N., Dang S.S., Wainwright S.R., Galea L.A., Hillard C.J., Gorzalka B.B. Upregulation of CB1 receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 2013, 237:333-337.
41. Meltzer H.Y., Roth B.L. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013, 123:4986-4991.
42. 1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17:58-65.
43. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, New York. 4th ed.
44. Peyron C., Petit J.M., Rampon C., Jouvet M., Luppi P.H. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 1998, 82:443-468.
45. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
46. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin-1A and serotonin-2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004, 14:1100-1109.
47. Santiago R.M., Barbieiro J., Lima M.M.S., Dombrowski P.A., Andreatini R., Vital M.A.B.F. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
48. Scholtissen B., Verhey F.R., Steinbusch H.W., Leentjens A.F. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm 2006, 113:59-73.
49. Sclafani A., Ackroff K. Reinforcement value of sucrose measured by progressive ratio operant licking in the rat. Physiol Behav 2003, 79:663-670.
50. Scopinho A.A., Scopinho M., Lisboa S.F., Correa F.M., Guimaraes F.S., Joca S.R. Acute reversible inactivation of the ventral medial prefrontal cortex induces antidepressant-like effects in rats. Behav Brain Res 2010, 214(2):437-442.
51. Sesack S.R., Deutch A.Y., Roth R.H., Bunney B.S. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 1989, 290:213-242.
52. Shirayama Y., Muneoka K., Fukumoto M., Tadokoro S., Fukami G., Hashimoto K., Iyo M. Infusions of allopregnanolone into the hippocampus and amygdala, but not into the nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus 2011, 21:1105-1113.
53. 1B receptors of medial prefrontal cortex modulate anxiogenic-like behaviors in rats. Neurosci Lett 2011, 504:325-329.
54. Sousa N., Almeida O.F., Wotjak C.T. A hitchhiker's guide to behavioral analysis in laboratory rodents. Genes Brain Behav 2006, 5:S5-S24.
55. 1A selective agonists. Eur J Pharmacol 1986, 128:295-298.
56. Stockmeier C.A., Shapiro L.A., Dilley G.E., Kolli T.N., Friedman L., Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 1998, 18:7394-7401.
57. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
58. Thierry A.M., Gioanni Y., Degenetais E., Glowinski J. Hippocampo-prefrontal cortex pathway: anatomical and electrophysiological characteristics. Hippocampus 2000, 10:411-419.
59. Treadway M.T., Zald D.H. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011, 35:537-555.
60. Vertes R.P. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 2004, 51:32-58.
61. Vitek J.L. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Dis 2002, 17:S69-S72.
62. Wallace T.L., Stellitano K.E., Neve R.L., Duman R.S. Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety. Biol Psychiatry 2004, 56:151-160.
63. 1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience 2009, 162:1091-1100.
64. Winter C., von Rumohr A., Mundt A., Petrus D., Klein J., Lee T., Morgenstern R., Kupsch A., Juckel G. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007, 184:133-141.
65. 2A receptors and the serotonin transport site in rat brain. J Psychiatric Res 1999, 33:17-22.
66. 2A/2C receptor stimulation in the rat. Brain Res 2010, 1312:127-137.
67. Zhang X.Q., Egeland M., Svenningsson P. Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology 2011, 218:621-634.